ING Group’s Global Blood Therapeutics, Inc. GBT Stock Holding History

ING Group’s Portfolio GBT Stock Details GBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-6,000	Closed	-$316K	–	797
2019 Q2	$316K	Buy	+6,000	New	+$345K	0.01%	648
2018 Q3	–	Sell	-43,483	Closed	-$1.97M	–	885
2018 Q2	$1.97M	Buy	+43,483	New	+$1.98M	0.04%	220
2018 Q1	–	Sell	-136,175	Closed	-$5.36M	–	852
2017 Q4	$5.36M	Buy	+136,175	New	+$5.09M	0.09%	127
2017 Q3	–	Sell	-24,942	Closed	-$682K	–	932
2017 Q2	$682K	Sell	24,942 -18,978	-43%	-$565K	0.01%	395
2017 Q1	$1.62M	Buy	+43,920	New	+$1.11M	0.03%	277

Other funds holding GBT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

ING Group's GBT Position: Q3 2019 in Review

ING Group sold out of Global Blood Therapeutics, Inc. (GBT) in Q3 2019, closing a stake of 6,000 shares — an estimated $316K sold.

ING Group first reported a position in GBT in Q1 2017 and held it in 5 quarters. The position peaked at $5.36M in Q4 2017. 208 funds tracked by Wall St. Rank hold GBT as of Q3 2019.

ING Group reported no remaining Global Blood Therapeutics, Inc. position as of Q3 2019 after selling out during the quarter.
ING Group sold 6,000 Global Blood Therapeutics, Inc. shares in Q3 2019, an estimated $316K.
ING Group first reported a position in Global Blood Therapeutics, Inc. in Q1 2017 and held it in 5 quarters.
ING Group's Global Blood Therapeutics, Inc. position peaked at $5.36M in Q4 2017.
208 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q3 2019.

Based on ING Group's 13F filing for Q3 2019, filed 8 Nov 2019.